menu search

CBIO / Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sale is part of the ongoing strategic process that we announced in. Read More
Posted: May 23 2022, 10:01
Author Name: Benzinga
Views: 102171

CBIO News  

Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today?

By InvestorPlace
February 28, 2023

Why Is Catalyst Biosciences (CBIO) Stock Up 55% Today?

Catalyst Biosciences (NASDAQ: CBIO ) stock is rocketing higher on Tuesday after the company announced an asset purchase agreement with GC Biopharma. T more_horizontal

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

By Benzinga
May 23, 2022

Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex

Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals more_horizontal


Search within

Pages Search Results: